Companies › Implicit Bioscience
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Cardiovascular, Respiratory; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ic14 (IC14) Monocyte differentiation antigen CD14 inhibitor | CD14 | Phase 2 | Acute Respiratory Distress Syndrome; Acute Decompensated Heart Failure; STEMI | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06556810 | Ic14 (IC14) | Phase 1 | Acute Decompensated Heart Failure | Cardiovascular | Apr 2026 |
| NCT06678074 | Ic14 (IC14) | Phase 1 | STEMI | Cardiovascular | Jun 2026 |
| NCT06513949 | Ic14 (IC14) | Phase 2 | Acute Respiratory Distress Syndrome | Respiratory | Mar 2029 |
–
PPD Development, LP Connect Biopharm Abcentra Aqualung Therapeutics Upstream Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.